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Supplementary Fig. 1
Supplementary Fig.1. Validation of anti-CD8 monoclonal antibody for immunostaining. CD8 staining
was detected on spleen section of C57Bl6 mouse but not on spleen section of lymphocyte-deficient
Rag1-/- mouse. Bar scale 40µm.
Isotype Control Anti-CD8
Supplementary Fig. 2
Supplementary Fig.2. Validation of anti-CD8 monoclonal antibody for immunostaining. At day 3 after MI, ischemic
heart tissue sections were stained either with rat anti-mouse IgG2b isotype or with anti-CD8 monoclonal antibody.





Supplementary Fig.3. Following MI, CD8+ T cells infiltration was detected in both infarct and peri-infarct areas.
Upper panel, immunostaining in the ischemic myocardium at day 3 after MI showing CD8+ T infiltration (Green).
Lower panel, CD8 immunostaining at day 3 after MI in CD8-depleted mice. Scale bar 500 µm.
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Supplementary Fig.4. Myocardial infarction induces time-dependent recruitment of effector and central memory
CD8+ T cells. Proportion of CD44+CCR7high central memory and CD44+CCR7low effector memory CD8+ T cells in the
ischemic heart at day 1 (n=6), 3 (n=7) and 7 (n=8) after MI. mean values ± SEM are represented. P values were




















Supplementary Fig.5. Myocardial infarction induces time-dependent activation of CD8+ T cells in mediastinal lymph
nodes. (a) Representative examples and quantitative analysis of CD8+ T cell expressing CD69 in mediastinal lymph
nodes in MI (Grey, n=6/9 at day 1/7) and Sham operated (White, n=6/timepoint) mice. Representative example and
quantitative analysis of CD8+ T cell expressing CD107a in mediastinal lymph nodes (n=6-8 mice per group/time point). P
values were calculated using two-tailed Mann-Whitney test at each time point.
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Supplementary Fig.6. CD8+ T cells release Granzyme B in peri infarct area. Immunostaining in the ischemic





Supplementary Fig.7. CD4+ T cells regulate CD8+ T cell trafficking in the context of acute MI. C57Bl6 Wild-type
mice received intraperitoneal injection of anti-CD4 depleting monoclonal antibody (Blue filled)(150 µg/mice) or
isotype control (Blue borderline) one day before coronary occlusion and CD8+ T cells were quantified in the blood
(A) and in the spleen (B) at day 1 and day 3 after MI (CTR n=4/time point, CD4 Depleted n=5/time point). To
evaluate the impact of CD4 depletion on CD8+ T cell mobilization from the spleen to the blood, the Blood/Spleen
ratio was calculated at day 1 (C). P values were calculated using two-tailed Mann-Whitney test.
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6 hours after antibody injection (Blood)
Supplementary Fig. 8
Supplementary Fig.8. mAb CD8 treatment quickly depletes circulating CD8+ T cells. Quantitative analysis of
CD8+ T cell staining in the blood of C57BL/6J mice 6 hours after treatment with isotype control (CTR, white) or
the CD8 mAb depleting antibody (CD8 Depleted, Grey) (n=4/Group). P values were calculated using two-tailed
Mann-Whitney test.
CD8+ T cells (Blood)
















Blood CD8+ T cells 





















Supplementary Fig.9. mAb CD8 treatment efficiently depletes circulating CD8+ T cells. Quantitative analysis of
CD8+ T cell staining in the blood of C57BL/6J mice treated with isotype control (CTR, Black box) or the CD8 mAb
(CD8 Depleted, white circle) until Day 21 (n=6/group/time point); mean values ± SEM are represented, ***
P<0.001. P values were calculated using two-tailed Mann-Whitney test at each time point.
Spleen CD8+ T cells





















Supplementary Fig.10. mAb CD8 treatment efficiently depletes spleen CD8+ T cells. Quantitative analysis
(right) of CD8+ T cell staining in the spleen of C57BL/6J mice treated with isotype control (CTR, black box) or with
the CD8 mAb (CD8 Depleted, white circle) (n=6/group/time point); mean values ± SEM are represented, ***
P<0.001. P values were calculated using two-tailed Mann-Whitney test at each timepoint.
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Supplementary Fig. 11
A B
Supplementary Fig.11. (A) Baseline echocardiography-derived parameters before isotype (White circle)
or CD8 monoclonal antibody treatment (Grey circle) (n=10/group) and (B) heart rate at day 21 after MI
(CTR n=8, CD8 depleted n=9).
Supplementary Fig. 12
CTR CD8 Depleted
Supplementary Fig.12. mAb CD8 treatment reduces infarct size at Day 21. Representative photomicrographs of
infarct size evaluation using Masson Trichrome staining on sections from the entire heart of isotype-treated or




Supplementary Fig.13. mAb CD8 treatment limits deleterious post-ischemic cardiac remodeling at Day 21 in
females C57BL/6 mice. A, Representative photomicrographs and quantification of infarct size evaluation using
Masson Trichrome staining on sections of isotype-treated (White circle) or anti-CD8 depleted (black circle) mice
at day 21 after MI. B, Quantification of LV ejection fraction at day 21 by echocardiography, (CTR n=8 and CD8
















Supplementary Fig.14. CD8+ T depletion decreases pro-fibrotic signature in infarcted heart. Quantitative
evaluation of Col1a1 and Col1a3 mRNA levels within the ischemic myocardium, on day 7 after MI in CTR















































Supplementary Fig.15. The CD8 T cell depleting antibody improves heart function and reduces infarct size at
later stage. (a) Representative photomicrographs and quantitative analysis of infarct size evaluation using Masson
trichrome staining, in the 2 groups of mice at day 56 after MI. (n=6 CTR white and n= 5 CD8 Depleted Grey). (b)
Representative photomicrographs and quantitative analysis of myocardial fibrosis evaluated by Sirius Red staining, in the
2 groups of mice at day 56 after MI (n=6 CTR white and n= 5 CD8 Depleted Grey). P values were calculated using two-
tailed Mann-Whitney test. bar scale 200 um.
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Supplementary Fig.16. The CD8 T cell depleting antibody had no impact on CD4+ T cell trafficking in infarcted
hearts. Cell suspensions from infarcted hearts of control (Black box) or CD8 depleted (White circle) C57BL/6J mice
were stained and analyzed by flow cytometry at different time points after MI. (a) CD4+ T lymphocytes were
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Supplementary Fig.17. The CD8 T cell depleting antibody had no impact on B cell trafficking in infarcted hearts. Cell
suspensions from infarcted hearts of control (White) or CD8 depleted (Grey) C57BL/6J mice were stained and analyzed
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Supplementary Fig.18. The CD8 T cell depleting antibody had no impact on NK and NKT cell trafficking in infarcted
hearts. Cell suspensions from infarcted hearts of control (White) or CD8 depleted (Grey) C57BL/6J mice were stained
and analyzed by flow cytometry 5 days after MI. (a) NKT were identified as CD45+NK1.1+CD3+ cells and NK were













































































































Supplementary Fig.19. The CD8 T cell depleting antibody had no impact on myeloid cell trafficking in infarcted
hearts. Cell suspensions from infarcted hearts of control (Black box) or CD8 depleted (White circle) C57BL/6J mice
were stained and analyzed by flow cytometry at different time points after MI. (a) Classical monocytes were
identified as CD11bhi Ly6G¾ F4/80¾ Ly6Chigh. (b) Non-classical monocytes were identified as CD11bhi Ly6G¾ F4/80¾
Ly6Clow. (c) Neutrophils were identified as CD11b+ Ly6G+ (gated on CD45+ cells)Data are representative of 6 mice
















































Supplementary Fig.20. The CD8 T cell depleting antibody had no impact on macrophage content in infarcted
hearts. Cell suspensions from infarcted hearts of control (White) or CD8 depleted (Grey) C57BL/6J mice were
stained and analyzed by flow cytometry 5 days after MI. Macrophages were identified as CD45+CD11b+F4/80+ cells
(CTR n=5 and CD8 Depleted n=8).
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Supplementary Fig.21. The CD8 T cell depleting antibody had no impact on dendritic cell content in infarcted
hearts. Cell suspensions from infarcted hearts of control (White) or CD8 depleted (Grey) C57BL/6J mice were
stained and analyzed by flow cytometry 5 days after MI. Dendritic cells were identified as CD45+F4/80-
CD11c+MHCII+ cells (CTR n=5 and CD8 Depleted n=8).
TUNEL/DAPI/Granzyme B
Supplementary Fig. 22
Supplementary Fig.22. Granzyme B colocalizes with apoptotic cells in the infarcted hearts.
Granzyme B immunostaining (Red) and TUNEL staining (Green) in the infarcted heart of WT
C57BL/6J mice at day 3 after MI. Nuclei were stained using DAPI (Blue). Scale bar 20 µm.
Supplementary Fig. 23
Supplementary Fig.23. Characterization of TUNEL+ cells in ischemic heart tissue. Immunofluorescent
staining at day 3 showed that apoptotic cardiomyocytes in ischemic heart tissue. TUNEL (Pink), Troponin T










Supplementary Fig.24. The CD8 T cell depleting antibody reduces infarct size at day 3. (a) Representative
photomicrographs and quantitative analysis of infarct size evaluation using TriphenylTetrazolium Chloride (TTC)
staining, in the 2 groups of mice at day 3 after MI. CTR (White) and CD8 depleted (Grey) (CTR n=6, CD8 Depleted n=5).
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Supplementary Fig. 25






































































































































































































































































Supplementary Fig.25. The CD8+ T cell depleting antibody promotes a phenotypic switch of tissue macrophages
toward a less inflammatory profile. (a) At Day 3 after MI, heart tissue macrophages defined as
CD45+CD11B+Ly6G-F4/80+ cells were cell sorted and (b) Il-1b, Tnf-a and iNOS mRNA levels were measured by
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Supplementary Fig. 26
Supplementary Fig.26. The CD8+ T cell depleting antibody promotes a macrophage phenotype associated with
alternative activation. Cell suspensions from infarcted hearts of control (Black box) or CD8 depleted (White circle)
C57BL/6J mice were stained and analyzed by flow cytometry at different time points after MI. “Alternatively-
activated” macrophages were identified as CD45+CD11b+Ly6G¾ Ly6C+F4/80+CD206+. Data are representative of 6
mice per group at each time point. Mean values ± SEM are shown. P values were calculated using two-tailed Mann-
Whitney test at each time point.
M2 macrophages (Heart)























Supplementary Fig.27. Granzyme B is not expressed in the infarcted hearts of GzmB-/-mice. Granzyme B
immunostaining (Red) in the infarcted heart (Upper panels) and the spleen (Lower panels) of WT C57BL/6J






Supplementary Fig.28. Granzyme B deficient CD8+ T cells infiltrate ischemic heart. Representative
examples of CD8+ T cell infiltration (green) in the heart of C57BL/6J mice or GzmB-/- mice at day 3 after
MI. Inf for infarct area. Scale bar 50 µm.
Supplementary Fig. 29
Supplementary Fig.29. Decreased Mmp9 in the infarcted hearts of GzmB-/- mice. Mmp9 mRNA
levels measured by qPCR in infarcted heart at Day 3 after MI, (n=9/group). P values were calculated































Supplementary Fig.30. Granzyme B deficiency trends to reduce MI-related mortality.
















Before activation After activation
Supplementary Fig. 31
Supplementary Fig.31. Validation of CD8+ T cell activation in vitro. Flow cytometry characterization of
purified splenic CD8+ T cells before and after in vitro activation.
Supplementary Fig. 32

























































































































































































































































































































































Exclusion of dead cells
Supplementary Fig.32. CD8+ T cell purity after isolation. Representative examples of CD3+CD8+ T cells before
and after purification, using the CD8 cell isolation kit (Miltenyi Biotec) according to manufacturer’s instructions.
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Supplementary Fig.33. Reconstitution of CD8+ T cell pool in resupplemented Rag1-/-mice. (a) Experimental
design of Rag1-/- mice injected with either CD8-depleted splenocytes (White) or CD8-depleted splenocytes re-
supplemented with wild-type (Grey) or GzmB-/- (Green) CD8+ T cells, 3 weeks before MI. (b) Cell suspensions
from infarcted hearts of reconstituted Rag1-/- mice were stained and analyzed by flow cytometry at day 3 after
MI. CD8+ T cells in the heart were identified as CD45+CD3+CD8+. (c) Cell suspensions from spleen of
reconstituted Rag1-/- mice were stained and analyzed by flow cytometry at day 3 after MI. CD8+ T cells in the
spleen were identified as CD45+ CD3+ CD8+. Data are representative of 5 mice per group at each time point. P
values were calculated using two-tailed Kruskal-Wallis test.
Supplementary Fig. 34




































































































































































































Baseline Day 1 Day 3
Supplementary Fig.34. Mouse anti-swine mAb CD8 induced delayed CD8 depletion. Blood CD8+ T cells were
quantified in the blood at different time points after mAb CD8 injection (15mg/kg, IV) in female pig. CD8+ T
cells were defined as CD79-CD3+CD4-CD8+. Cells.











































































































Supplementary Fig.35. Experimental protocol of CD8 depletion in female pigs in the context of myocardial
ischemia-reperfusion.
Supplementary Fig. 36
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Supplementary Fig.37. Echocardiography parameters at Day 14 in Control (PBS), Low and High
CD8-depleted groups (Control n=6, Low depletion n=5 and high depletion n=5). P values were
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Supplementary Fig.38. Plasma Granzyme B levels in pigs. Plasma Granzyme B levels was measured at Day 1, 3 and
14 after heart ischemia/reperfusion in control (White box, N=4) and CD8 depleted (High depletion, Dark box, N=5)












Day 1 Day 3 Day 14
Parameters  
Myocardial biopsy, n 17 
Time between myocardial infarction and LVAD (days) 14 (5;21) 
Male Sex 88 % 
Age, years  55 (52;61) 
Hypertension 41% 
Hypercholesterolemia 41% 
Diabetus mellitus 23% 
Current smokers 59% 
Chronic kidney disease 12% 
STEMI  88% 
No STEMI 12% 
PCI 70% 
Thrombolyse 0% 
Coronary artery bypass surgery 12% 
Aspirin 100% 
Heparin or Low Molecular Weight Heparin 100% 
Cardiogenic shock 100% 
Heart transplantation after LVAD 41% 
 
Supplementary Table 1: characteristics of included patients in histopathological study. LVAD, left 
ventricle assist device; PCI, Percutaneous coronary intervention; STEMI, ST Elevation Myocardial 
Infarction. Data are expresses as median (1stIQR, 3rdIQR) or percentage. 
  < 8.9 pg/mL 
(N=523) 
≥ 8.9 pg/mL 
(N=523) 
p† 
Demographic and risk factors    
Male Sex, No (%) 402 (76.9) 388 (74.2) 0.31 
Age, yr ‡ 63.0 ± 13.4 64.4 ± 14.0 0.11 
Hypertension, No (%) 266 (50.9) 276 (52.8) 0.54 
Hypercholesterolemia, No (%) 231 (44.2) 229 (43.8) 0.90 
Diabetus mellitus, No (%) 111 (21.2) 98 (18.7) 0.31 
Family history of CAD, No (%) 152 (29.1) 138 (26.4) 0.33 
Current smokers, No (%) 222 (42.4) 191 (36.5) 0.05 
Prior myocardial infarction, No (%) 69 (13.2) 77 (14.7) 0.48 
Prior PCI or CABG, No (%) 73 (14.0) 82 (15.7) 0.43 
Prior stroke or TIA, No (%) 18 (3.4) 22 (4.2) 0.52 
Prior heart failure, No (%) 11 (2.1) 18 (3.4) 0.19 
Chronic kidney disease, No (%) 22 (4.2) 18 (3.4) 0.52 
Clinical presentation   
Body mass index, kg/m² ‡ 26.8 ± 4.6 26.8 ± 4.3 0.94 
Systolic blood pressure at admission, 
mmHg‡ 
144.8 ± 28.7 146.7 ± 27.0 0.26 
Heart rate at admission, beat/min‡ 79.2 ± 20.4 77.6 ± 18.4 0.18 
STEMI, No (%) 297 (56.8) 269 (51.4) 0.08 
STEMI and/or revascularisation, No (%)   
 
  0.22 
  No STEMI  226 (43.2)  254 (48.6)   
  STEMI alone  63 (12.0)  55 (10.5)   
  STEMI and revascularisation  234 (44.7)  214 (40.9)   
Killip Max >=2, No (%) 86 (16.4) 99 (18.9) 0.29 
GRACE score‡ 136.8 ± 34.3 137.5 ± 34.6 0.76 
Left ventricular ejection fraction, % ‡ 51.6 ± 10.5 52.5 ± 11.2 0.17 
Baseline biological exams 
 
CRP, mg/L* 5.0 [3.0 ; 9.8] 5.0 [3.0 ; 10.7] 0.78 
In-hospital Management   
PCI, No (%) 420 (80.3) 399 (76.3) 0.12 
Thrombolyse, No (%) 45 (8.6) 41 (7.8) 0.65 
Coronary artery bypass surgery, No (%) 13 (2.5) 27 (5.2) 0.02 
Statins, No (%) 475 (90.8) 464 (88.7) 0.26 
Beta-blockers, No (%) 431 (82.4) 432 (82.6) 0.94 
Calcium channel blockers, No (%) 125 (23.9) 132 (25.2) 0.62 
ACE inhibitors or ARB, No (%) 226 (43.2) 244 (46.7) 0.26 
Nitrated derivatives, No (%) 251 (48.0) 256 (48.9) 0.76 
Aspirin, No (%) 502 (96.0) 513 (98.1) 0.04 
Clopidogrel, No (%) 403 (77.1) 410 (78.4) 0.60 
Heparin, No (%) 231 (44.2) 235 (44.9) 0.80 
Low Molecular Weight Heparin, No (%) 293 (56.0) 306 (58.5) 0.42 
Diuretics, No (%) 137 (26.2) 157 (30.0) 0.17 
Glycoprotein IIb/IIIa inhibitors, No (%) 231 (44.2) 175 (33.5) 0.0004 
Digitalis glycosides, No (%) 3 (0.6) 4 (0.8) 1 
†p is given by unpaired two-sided Student t or Wilcoxon rank-sum (continuous variables) and exact 
Pearson X² or Fisher exact test (categorical variables) 
‡ Mean ± sd, *Median, Q1, Q3 
 
Supplementary Table 2: Characteristics of included patients according to baseline plasma 
Granzyme B level. CAD, Coronary Artery Disease; PCI, Percutaneous coronary intervention; 




Supplementary Table 3 
 
 Characteristics HR CI 95% P-value 
Granzyme B median ³8.9 2.261 (1.221 - 4.188) 0.0095 
Female gender 0.879 (0.463 - 1.671) 0.6943 
Age 1.037 (1.002 - 1.073) 0.0366 
Hypertension 0.968 (0.492 - 1.905) 0.9253 
BMI >=30 0.835 (0.395 - 1.766) 0.6370 
Current smokers 0.953 (0.402 - 2.255) 0.9120 
Hypercholesterolemia 1.170 (0.665 - 2.056) 0.5859 
Diabetes mellitus 1.631 (0.873 - 3.048) 0.1249 
STEMI and/or revascularisation     0.0646 
STEMI + revascularisation 0.464 (0.207 - 1.043)   
STEMI without revascularisation 1.490 (0.627 - 3.542)   
No STEMI 1.000     
Killip Max >=2 1.495 (0.773 - 2.888) 0.2320 
LV ejection 
fraction >=40 1.576 (0.821 - 3.027) 0.1715 
Prior stroke or TIA 1.535 (0.602 - 3.913) 0.3691 
Prior myocardial infarction 0.478 (0.217 - 1.053) 0.0671 
Prior heart failure 7.677 (3.148 - 18.72) <.0001 
Chronic kidney disease 1.798 (0.817 - 3.961) 0.1451 
Prior cancer 2.173 (1.059 - 4.46) 0.0343 
Family history of CAD 0.785 (0.349 - 1.765) 0.5589 
Statins 1.571 (0.711 - 3.471) 0.2636 
Beta-blockers 0.392 (0.218 - 0.704) 0.0017 
Diuretics 1.068 (0.566 - 2.017) 0.8388 
Clopidogrel 2.296 (0.912 - 5.779) 0.0776 
Low Molecular Weight 
Heparin 0.374 (0.195 - 0.718) 0.0031 
GPIIb/IIIa inhibitors 0.827 (0.401 - 1.708) 0.6084 
Coronary artery bypass surgery 0.572 (0.128 - 2.55) 0.4639 
CPK peak       
CPK > 1701 3.334 (1.082 - 10.279) 0.0360 
CPK ]595 ; 1701] 1.318 (0.467 - 3.718) 0.6021 
CPK ]212 ; 595] 0.722 (0.247 - 2.114) 0.5524 
CPK Missing 2.935 (1.233 - 6.987) 0.0150 
CPK <= 212 1.000     
 
Supplemental Table 3: Multivariable logistic regression analysis of risk factors for 1-year 
mortality, using a multivariable Cox proportional-hazards model. HR, Hazard Ratio, BMI, 
Body Mass Index ; STEMI, ST Elevation Myocardial Infarction ; LV, Left Ventricle ; CAD ; 




Fluorochrome Clone Supplier Reference Isotype 
CD3e PerCP 145-2C11 BD Biosciences 553067 Armenian Hamster IgG1, K 
CD3e PerCP 145-2C11 eBioscience 45-0031-82 Armenian Hamster IgG1, K 
CD3e BV421 145-2C11 BD Biosciences 562600 Armenian Hamster IgG1, K 
CD3e PE-Cy7 145-2C11 BD Biosciences 552774 Armenian Hamster IgG1, K 
CD4 FITC RM4-5 eBioscience 11-0042-85 Rat IgG2a, k 
CD4 PE RM4-5 eBioscience 12-0043-82 Rat IgG2b, k 
CD8a AF700 53-6.7 BD Biosciences 557959 Rat IgG2a, k 
CD8a APC 53-6.7 BD Biosciences 553035 Rat IgG2a, k 
CD45R (B220) V500 RA3-6B2 BD Biosciences 561226 Rat IgG2a, k 
CD19 PE 1D3 eBioscience 12-0193-82 Rat IgG2a, k 
CD19 PE-Cy7 1D3 BD Biosciences 552854 Rat IgG2a, k 
CD107 APC-Cy7 1D4B BioLegend 121615 Rat IgG2a, k 
CD69 PE H1.2F3 eBioscience 12-0691-83 Armenian Hamster IgG1, K 
CD69 BV421 H1.2F3 BD Biosciences 562920 Armenian Hamster IgG1, K 
CD45 FITC 30-F11 BD Biosciences 553079 Rat IgG2b, k 
CD45 PerCP 30-F11 BD Biosciences 557235 Rat IgG2b, k 
CD45 AF700 30-F11 BD Biosciences 560510 Rat IgG2b, k 
CD11b PE-Cy7 M1/70 eBioscience 25-0112-82 Rat IgG2b, k 
CD11c PerCP-Cy5.5 HL3 BD Biosciences 560584 Armenian Hamster IgG1, K 
LY6G PE 1A8 BD Biosciences 551461 Rat IgG2a, k 
LY6C FITC AL-21 BD Biosciences 553104 Rat IgM, k 
F4/80 APC A3-1 Bio-Rad MCA497APCT Rat IgG2b, k 
F4/80 PE BM8 eBioscience 12-4801-82 Rat IgG2a, k 
CD64 BV421 x54-5/7.1 BioLegend 139309 Mouse IgG1, k 
CD44 APC IM7 eBioscience 17-0441-83 Rat IgG2b, k 
CD206 AF647 C068C2 BioLegend 141712 Rat IgG2a, k 
MHCII PerCP-eFluor 710 M5/114.15.2 eBioscience 46-5321-82 Rat IgG2b, k 
CCR7 PE-Cy7 4B12 eBioscience 17-1971-82 Rat IgG2a, k 
NK1.1 PE-Cy7 PK136 eBioscience 25-5941-82 Mouse IgG2a, k 
NK1.1 APC PK136 eBioscience 17-5941-82 Mouse IgG2a, k 
CD172A No Conjugated - Monoclonal Antibody Center PG2031 IgG2b 
MSA3 (MHCII) No Conjugated - Monoclonal Antibody Center PG2006 IgG2a 
PG68A No Conjugated - Monoclonal Antibody Center PG2045 IgG1 
SWC8 No Conjugated MIL3 Abcam Ab34020 IgGM 
CD14 FITC TUK4 GENE TEX GTX43753 Mouse IgG2a 
CD163 PE 2A10/11 Abcam Ab194889 Mouse IgG1 
PG164A (CD8b) No Conjugated - Monoclonal Antibody Center PG2020 IgG2a 
CD4 PE-Cy7 74-124 Abcam Ab25408 Mouse IgG2a 
CD3e PerCP-Cy5.5 BB23-8E6-8C8 BD Biosciences 561478 Mouse IgG2a, k 
CD79a PE HM57 BD Biosciences 563777 Mouse IgG1 
 
Supplementary Table 4. General characteristics of antibodies used for flow cytometry 
characterization of immune cells. 
 
 
Secondary Antibody Fluorochrome Clone Supplier Reference 
Goat Anti-Mouse IgG2b APC-Cy7 Polyclonal Abcam ab130791 
Rat Anti-Mouse IgG2a PE-Cy7 RMG2a-62 BioLegend 407114 
Rat Anti-Mouse IgG1 PerCP-Cy5.5 RMG1-1 BioLegend 406612 
Rat Anti-mouse IgM APC Nov-41 BD Biosciences 550676 
 
Supplementary Table 5. General characteristics of secondary antibodies used for flow 




Gapdh Forward 5ʹ-CGTCCCGTAGACAAAATGGTGAA-3ʹ,  
Reverse 5ʹ-GCCGTGAGTGGAGTCATACTGGAA-CA-3ʹ;  
Granzyme B Forward 5ʹ-GTGCGGGGGACCCAAAGACCAAAC-3ʹ,  
Reverse: 5ʹ-GCACGTGGAGGTGAACCATCCTTATAT-3ʹ 
Il1b Forward 5’-GAAGAGCCCATCCTCTGTGA-3’,  
Reverse 5’-GGGTGTGCCGTCTTTCATTA-3’ 
Il6 Forward 5ʹ-TGACAACCACGGCCTTCCCTA-3ʹ,  
Reverse: 5ʹ-TCAGAATTGCCATTGCACAACTCTT-3’ 
Il10 Forward 5ʹ-ACTTCCCAGTCGGCCAGAGCCACAT-3ʹ,  
Reverse: 5ʹ-GATGACAGCGCCTCAGCCGCATCCT-3ʹ 
Tnf-a  Forward 5’-GATGGGGGGCTTCCAGAACT-3’,  
Reverse 5’-GATGGGGGGCTTCCAGAACT-3’  
Mmp9 Forward 5’-GCGTCATTCGCGTGGATAAGGAGT-3’,  
Reverse 5’-GTAGCCCACGTCGTCCACCTGGTT-3’ 
 
Supplementary Table 6. The primer sequences used for quantitative real-time PCR.  
